Optimising Radioligand Therapy for Patients with Gastro-Entero-Pancreatic Neuroendocrine Tumours: Expert Opinion from an Italian Multidisciplinary Group.
Diagnostic–therapeutic care pathway
Expert opinion
Gastro-entero-pancreatic neuroendocrine tumours
Italy
Lutetium (177Lu) oxodotreotide
Organizational implications, radioligand therapy
Journal
Advances in therapy
ISSN: 1865-8652
Titre abrégé: Adv Ther
Pays: United States
ID NLM: 8611864
Informations de publication
Date de publication:
21 Nov 2023
21 Nov 2023
Historique:
received:
24
07
2023
accepted:
17
10
2023
medline:
21
11
2023
pubmed:
21
11
2023
entrez:
21
11
2023
Statut:
aheadofprint
Résumé
Radioligand therapy (RLT) with lutetium (
Identifiants
pubmed: 37987917
doi: 10.1007/s12325-023-02714-8
pii: 10.1007/s12325-023-02714-8
doi:
Types de publication
Journal Article
Review
Langues
eng
Informations de copyright
© 2023. The Author(s).
Références
Pavel M, Oberg K, Falconi M, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31:844–60.
pubmed: 32272208
doi: 10.1016/j.annonc.2020.03.304
Roll W, Weckesser M, Seifert R, Bodei L, Rahbar K. Imaging and liquid biopsy in the prediction and evaluation of response to PRRT in neuroendocrine tumors: implications for patient management. Eur J Nucl Med Mol Imaging. 2021;48:4016–27.
pubmed: 33903926
doi: 10.1007/s00259-021-05359-3
European Medicines Agency. Summary of product characteristics - Lutathera. 2017. European Medicines Agency. https://www.ema.europa.eu/en/documents/product-information/lutathera-epar-product-information_en.pdf . Accessed 29 Apr 2022.
Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 trial of
pubmed: 28076709
doi: 10.1056/NEJMoa1607427
Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [
pubmed: 18445841
doi: 10.1200/JCO.2007.15.2553
Merkel C, Whicher CH, Bomanji J, et al. Realising the potential of radioligand therapy: policy solutions for the barriers to implementation across Europe. Eur J Nucl Med Mol Imaging. 2020;47:1335–9.
pubmed: 32170345
doi: 10.1007/s00259-020-04745-7
Severi S, Grassi I, Nicolini S, Sansovini M, Bongiovanni A, Paganelli G. Peptide receptor radionuclide therapy in the management of gastrointestinal neuroendocrine tumors: efficacy profile, safety, and quality of life. Onco Targets Ther. 2017;10:551–7.
pubmed: 28203088
doi: 10.2147/OTT.S97584
Bartolomei M, Berruti A, Falconi M, et al. Clinical management of neuroendocrine neoplasms in clinical practice: a formal consensus exercise. Cancers (Basel). 2022;14(10):2501.
pubmed: 35626105
doi: 10.3390/cancers14102501
Green BN, Johnson CD, Adams A. Writing narrative literature reviews for peer-reviewed journals: secrets of the trade. J Chiropr Med. 2006;5:101–17.
pubmed: 19674681
doi: 10.1016/S0899-3467(07)60142-6
Eriksen MB, Frandsen TF. The impact of patient, intervention, comparison, outcome (PICO) as a search strategy tool on literature search quality: a systematic review. J Med Libr Assoc. 2018;106:420–31.
pubmed: 30271283
doi: 10.5195/jmla.2018.345
Osborn A. Applied imagination: principles and procedures of creative problem solving. New York: Charles Scribner’s Sons; 1953.
Ambrosini V, Kunikowska J, Baudin E, et al. Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. Eur J Cancer. 2021;146:56–73.
pubmed: 33588146
doi: 10.1016/j.ejca.2021.01.008
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.
pubmed: 19097774
doi: 10.1016/j.ejca.2008.10.026
World Health Organization. WHO handbook for reporting results of cancer treatment. 1979. Geneva, Switzerland. https://apps.who.int/iris/bitstream/handle/10665/37200/WHO_OFFSET_48.pdf?sequence=1&isAllowed=y . Accessed 29 July 2022.
Rinke A, Muller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27:4656–63.
pubmed: 19704057
doi: 10.1200/JCO.2009.22.8510
Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the United States, national cancer institute of Canada. J Natl Cancer Inst. 2000;92:205–16.
pubmed: 10655437
doi: 10.1093/jnci/92.3.205
Caplin ME, Pavel M, Cwikla JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371:224–33.
pubmed: 25014687
doi: 10.1056/NEJMoa1316158
de Mestier L, Dromain C, d’Assignies G, et al. Evaluating digestive neuroendocrine tumor progression and therapeutic responses in the era of targeted therapies: state of the art. Endocr Relat Cancer. 2014;21:R105–20.
pubmed: 24351682
doi: 10.1530/ERC-13-0365
Merino-Casabiel X, Aller J, Arbizu J, et al. Consensus document on the progression and treatment response criteria in gastroenteropancreatic neuroendocrine tumors. Clin Transl Oncol. 2018;20:1522–8.
pubmed: 29766455
doi: 10.1007/s12094-018-1881-9
Rozenblum L, Mokrane FZ, Yeh R, et al. Imaging-guided precision medicine in non-resectable gastro-entero-pancreatic neuroendocrine tumors: a step-by-step approach. Eur J Radiol. 2020;122: 108743.
pubmed: 31783345
doi: 10.1016/j.ejrad.2019.108743
Hope TA, Abbott A, Colucci K, et al. NANETS/SNMMI procedure standard for somatostatin receptor-based peptide receptor radionuclide therapy with
pubmed: 31263080
doi: 10.2967/jnumed.118.230607
Riihimaki M, Hemminki A, Sundquist K, Sundquist J, Hemminki K. The epidemiology of metastases in neuroendocrine tumors. Int J Cancer. 2016;139:2679–86.
pubmed: 27553864
doi: 10.1002/ijc.30400
Cives M, Pelle E, Rinzivillo M, et al. Bone metastases in neuroendocrine tumors: molecular pathogenesis and implications in clinical practice. Neuroendocrinol. 2021;111:207–16.
doi: 10.1159/000508633
Altieri B, Di Dato C, Martini C, et al. Bone metastases in neuroendocrine neoplasms: from pathogenesis to clinical management. Cancers (Basel). 2019;11(9):1332.
pubmed: 31500357
doi: 10.3390/cancers11091332
Sabet A, Khalaf F, Haslerud T, et al. Bone metastases in GEP-NET: response and long-term outcome after PRRT from a follow-up analysis. Am J Nucl Med Mol Imaging. 2013;3:437–45.
pubmed: 24116352
Ezziddin S, Sabet A, Heinemann F, et al. Response and long-term control of bone metastases after peptide receptor radionuclide therapy with
pubmed: 21764798
doi: 10.2967/jnumed.111.090373
Sabet A, Khalaf F, Yong-Hing CJ, et al. Can peptide receptor radionuclide therapy be safely applied in florid bone metastases? A pilot analysis of late stage osseous involvement. Nuklearmedizin. 2014;53:54–9.
pubmed: 24777355
doi: 10.3413/Nukmed-0614-13-08
Unger N, Ueberberg B, Schulz S, Saeger W, Mann K, Petersenn S. Differential expression of somatostatin receptor subtype 1–5 proteins in numerous human normal tissues. Exp Clin Endocrinol Diabetes. 2012;120:482–9.
pubmed: 22976314
doi: 10.1055/s-0032-1314859
Basu S, Ranade R, Thapa P. Metastatic neuroendocrine tumor with extensive bone marrow involvement at diagnosis: evaluation of response and hematological toxicity profile of PRRT with
pubmed: 26912977
doi: 10.4103/1450-1147.165353
Bergsma H, Konijnenberg MW, Kam BLR, et al. Subacute haematotoxicity after PRRT with
Baum RP, Kulkarni HR, Singh A, et al. Results and adverse events of personalized peptide receptor radionuclide therapy with
pubmed: 29682195
doi: 10.18632/oncotarget.24524
Guerra Liberal FDC, Tavares AAS, Tavares J. Palliative treatment of metastatic bone pain with radiopharmaceuticals: a perspective beyond strontium-89 and samarium-153. Appl Radiat Isot. 2016;110:87–99.
pubmed: 26773820
doi: 10.1016/j.apradiso.2016.01.003
Bouchet LG, Bolch WE, Goddu SM, Howell RW, Rao DV. Considerations in the selection of radiopharmaceuticals for palliation of bone pain from metastatic osseous lesions. J Nucl Med. 2000;41:682–7.
pubmed: 10768569
Scopel M, De Carlo E, Bergamo F, et al. Bone metastases from neuroendocrine tumors: clinical and biological considerations. Endocr Connect. 2022;11(7): e210568.
pubmed: 35671272
doi: 10.1530/EC-21-0568
Strosberg J, Kunz PL, Hendifar A, et al. Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with
pubmed: 32123969
doi: 10.1007/s00259-020-04709-x
Bober B, Saracyn M, Zareba K, et al. Early complications of radioisotope therapy with lutetium-177 and yttrium-90 in patients with neuroendocrine neoplasms-a preliminary study. J Clin Med. 2022;11(4):919.
pubmed: 35207193
doi: 10.3390/jcm11040919
Neri E, Bali MA, Ba-Ssalamah A, et al. ESGAR consensus statement on liver MR imaging and clinical use of liver-specific contrast agents. Eur Radiol. 2016;26:921–31.
pubmed: 26194455
doi: 10.1007/s00330-015-3900-3
Hayoz R, Vietti-Violi N, Duran R, Knebel JF, Ledoux JB, Dromain C. The combination of hepatobiliary phase with Gd-EOB-DTPA and DWI is highly accurate for the detection and characterization of liver metastases from neuroendocrine tumor. Eur Radiol. 2020;30:6593–602.
pubmed: 32601948
doi: 10.1007/s00330-020-06930-6
Malla S, Kumar P, Madhusudhan KS. Radiology of the neuroendocrine neoplasms of the gastrointestinal tract: a comprehensive review. Abdom Radiol (NY). 2021;46:919–35.
pubmed: 32960304
doi: 10.1007/s00261-020-02773-3
Dietrich CF, Nolsoe CP, Barr RG, et al. Guidelines and good clinical practice recommendations for contrast-enhanced ultrasound (CEUS) in the liver-update 2020 WFUMB in cooperation with EFSUMB, AFSUMB, AIUM, and FLAUS. Ultrasound Med Biol. 2020;46:2579–604.
pubmed: 32713788
doi: 10.1016/j.ultrasmedbio.2020.04.030
Knigge U, Capdevila J, Bartsch DK, et al. ENETS Consensus Recommendations for the standards of care in neuroendocrine neoplasms: follow-up and documentation. Neuroendocrinol. 2017;105:310–9.
doi: 10.1159/000458155
Airtum Working Group, Busco S, Buzzoni C, et al. Italian cancer figures–Report 2015: the burden of rare cancers in Italy. Epidemiol Prev. 2016;40:1–120.
Gusani NJ, Schubart JR, Wise J, et al. Cancer survivorship: a new challenge for surgical and medical oncologists. J Gen Intern Med. 2009;24(Suppl 2):S456–8.
pubmed: 19838850
doi: 10.1007/s11606-009-1010-0
Shapiro CL. Cancer survivorship. N Engl J Med. 2018;379:2438–50.
pubmed: 30575480
doi: 10.1056/NEJMra1712502
Aaronson NK, Mattioli V, Minton O, et al. Beyond treatment - psychosocial and behavioural issues in cancer survivorship research and practice. EJC Suppl. 2014;12:54–64.
pubmed: 26217166
doi: 10.1016/j.ejcsup.2014.03.005
Simard S, Thewes B, Humphris G, et al. Fear of cancer recurrence in adult cancer survivors: a systematic review of quantitative studies. J Cancer Surviv. 2013;7:300–22.
pubmed: 23475398
doi: 10.1007/s11764-013-0272-z
Horick NK, Manful A, Lowery J, et al. Physical and psychological health in rare cancer survivors. J Cancer Surviv. 2017;11:158–65.
pubmed: 27761785
doi: 10.1007/s11764-016-0573-0
Ratcliff C, Naik AD, Martin LA, Moye J. Examining cancer survivorship trajectories: exploring the intersection between qualitative illness narratives and quantitative screening instruments. Palliat Support Care. 2018;16:712–8.
pubmed: 29282156
doi: 10.1017/S1478951517000967
Campbell H, Hotchkiss R, Bradshaw N, Porteous M. Integrated care pathways. BMJ. 1998;316:133–7.
pubmed: 9462322
doi: 10.1136/bmj.316.7125.133
Jacka JM, Keller PJ. RACI Matrices. In: Jacka JM, Keller PJ, editors. Business process mapping: improving customer satisfaction. 2nd ed. Hoboken, NJ, USA: John Wiley & Sons; 2009. p. 255–76.
European Union. Council Directive 2013/59/Euratom of 5 December 2013 laying down basic safety standards for protection against the dangers arising from exposure to ionising radiation, and repealing Directives 89/618/Euratom, 90/641/Euratom, 96/29/Euratom, 97/43/Euratom and 2003/122/Euratom. 2013. EUR-Lex. https://eur-lex.europa.eu/eli/dir/2013/59/oj . Accessed 2 Mar 2023.
Chiesa C, Strigari L, Pacilio M, et al. Dosimetric optimization of nuclear medicine therapy based on the Council Directive 2013/59/EURATOM and the Italian law N. 101/2020. Position paper and recommendations by the Italian national Associations of Medical Physics (AIFM) and Nuclear Medicine (AIMN). Phys Med. 2021;89:317–26.
pubmed: 34583307
doi: 10.1016/j.ejmp.2021.07.001